down arrow

ARCA biopharma, Inc.

  • Market Cap: N/A
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US00211Y5069
USD
30.93
3.1 (11.14%)

Dec 04

NAS

 Click here to see other stocks
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

29.2531.16

52 Week

5.4931.16
Valuation
Technical
Day's Volume

CASH

110.37 k

Shareholding (Mar 2025)

FII

5.93%

Held by 25 FIIs

DII

55.55%

Held by 27 DIIs

Promoter

14.75%

How big is ARCA biopharma, Inc.?

22-Jun-2025

As of Jun 18, ARCA biopharma, Inc. has a market capitalization of 418.93 million and reported net sales of 0.00 million with a net profit of -78.08 million over the last four quarters. Shareholder's funds were 382.22 million, and total assets amounted to 396.02 million as of Dec 24.

As of Jun 18, ARCA biopharma, Inc. has a market capitalization of 418.93 million, categorizing it as a Micro Cap company.<BR><BR>As of Jun 18, the company reported net sales of 0.00 million for the latest four quarters, with a net profit of -78.08 million during the same period.<BR><BR>As of Dec 24, the company's shareholder's funds were 382.22 million, and total assets amounted to 396.02 million.

Read More

What does ARCA biopharma, Inc. do?

22-Jun-2025

ARCA biopharma, Inc. is a biopharmaceutical company focused on developing genetically-targeted therapies for cardiovascular diseases, with a market cap of approximately $418.93 million and a recent net profit of -$21 million. The company operates in the Pharmaceuticals & Biotechnology industry and is classified as a Micro Cap.

Overview: <BR>ARCA biopharma, Inc. is a biopharmaceutical company focused on developing genetically-targeted therapies for cardiovascular diseases, operating within the Pharmaceuticals & Biotechnology industry and classified as a Micro Cap.<BR><BR>Financial Snapshot: <BR>Most recent Net Profit: -21 Million (Quarterly Results - Mar 2025) <BR>Market cap: USD 418.93 Million (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: NA (Loss Making) <BR>Industry P/E: NA <BR>Dividend Yield: 66.58% <BR>Debt Equity: -0.96 <BR>Return on Equity: -21.31% <BR>Price to Book: 1.15<BR><BR>Contact Details: <BR>Address: 10170 Church Ranch Way, Suite 100, WESTMINSTER CO: 80021 <BR>Tel: 1 720 9402100 <BR>Fax: 1 302 6555049 <BR>Website: http://arcabio.com/

Read More

Who are in the management team of ARCA biopharma, Inc.?

22-Jun-2025

As of March 2022, the management team of ARCA biopharma, Inc. includes Robert Conway (Chairman), Dr. Michael Bristow (CEO), Dr. Linda Grais (Lead Independent Director), Dr. Anders Hove, Mr. Daniel Mitchell, and Dr. Raymond Woosley (Directors). They are responsible for the company's strategic direction and operations.

As of March 2022, the management team of ARCA biopharma, Inc. includes the following individuals:<BR><BR>- Mr. Robert Conway, Chairman of the Board<BR>- Dr. Michael Bristow, President, Chief Executive Officer, and Director<BR>- Dr. Linda Grais, Lead Independent Director<BR>- Dr. Anders Hove, Director<BR>- Mr. Daniel Mitchell, Director<BR>- Dr. Raymond Woosley, Director<BR><BR>This team oversees the strategic direction and operations of the company.

Read More

Is ARCA biopharma, Inc. technically bullish or bearish?

20-Sep-2025

As of September 5, 2025, ARCA biopharma, Inc. shows a mildly bullish trend with mixed signals from indicators, having outperformed the S&P 500 recently but underperformed year-to-date.

As of 5 September 2025, the technical trend for ARCA biopharma, Inc. has changed from bullish to mildly bullish. The current stance is mildly bullish, supported by a bullish MACD on the weekly timeframe and a bullish RSI on the monthly timeframe. However, the monthly KST is bearish, and the OBV shows a mildly bearish signal, indicating some mixed signals. The moving averages are bullish on the daily timeframe, which adds to the positive outlook. <BR><BR>In terms of performance, the stock has outperformed the S&P 500 over the past week and month, with returns of 2.66% and 8.72% respectively, but has significantly underperformed over longer periods, including a -14.49% year-to-date return compared to the S&P 500's 12.22%.

Read More
iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard
Icon
Unrated Stock - No Analysis Available
stock-summaryMojo Parameters
Mojo Parameters
Stock DNA
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 518 Million ()

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

53.81%

stock-summary
Debt Equity

-0.95

stock-summary
Return on Equity

-29.09%

stock-summary
Price to Book

1.51

Revenue and Profits:
Net Sales:
(Quarterly Results - Jun 2025)
Net Profit:
-25 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
100.32%
0%
100.32%
6 Months
159.05%
0%
159.05%
1 Year
48.56%
0%
48.56%
2 Years
40.85%
0%
40.85%
3 Years
1358.96%
0%
1358.96%
4 Years
1274.67%
0%
1274.67%
5 Years
-39.5%
0%
-39.5%

ARCA biopharma, Inc. for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions
News

Is ARCA biopharma, Inc. technically bullish or bearish?

As of 5 September 2025, the technical trend for ARCA biopharma, Inc. has changed from bullish to mildly bullish. The current stance is mildly bullish, supported by a bullish MACD on the weekly timeframe and a bullish RSI on the monthly timeframe. However, the monthly KST is bearish, and the OBV shows a mildly bearish signal, indicating some mixed signals. The moving averages are bullish on the daily timeframe, which adds to the positive outlook. In terms of performance, the stock has outperformed the S&P 500 over the past week and month, with returns of 2.66% and 8.72% respectively, but has significantly underperformed over longer periods, including a -14.49% year-to-date return compared to the S&P 500's 12.22%....

Read More
Announcements stock-summary
Icon
No announcement available
Corporate Actions stock-summary
Icon
No corporate action available
stock-summaryKey Factors
Quality key factors stock-summary
Factor
Value
Sales Growth (5y)
0
EBIT Growth (5y)
-281.82%
EBIT to Interest (avg)
-26.61
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.96
Sales to Capital Employed (avg)
0
Tax Ratio
0
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
100.00%
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
1.21
EV to EBIT
-1.04
EV to EBITDA
-1.04
EV to Capital Employed
5.75
EV to Sales
NA
PEG Ratio
NA
Dividend Yield
63.35%
ROCE (Latest)
-550.49%
ROE (Latest)
-21.31%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bullish
Mildly Bullish
RSI
Bearish
No Signal
Bollinger Bands
Bullish
Bullish
Moving Averages
Bullish (Daily)
KST
Bullish
Mildly Bearish
Dow Theory
Mildly Bullish
Mildly Bullish
OBV
Mildly Bullish
Mildly Bullish
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Mar 2025stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Domestic Funds

Domestic Funds

Held in 12 Schemes (23.77%)

Foreign Institutions

Held by 25 Foreign Institutions (5.93%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is 0.00% vs 0.00% in Jun 2024",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is -811.11% vs -80.00% in Jun 2024",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Jun'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-28.40",
          "val2": "-2.70",
          "chgp": "-951.85%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "-0.40",
          "chgp": "100.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-24.60",
          "val2": "-2.70",
          "chgp": "-811.11%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is 0.00% vs 0.00% in Dec 2023",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is -1,479.25% vs 46.46% in Dec 2023",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-88.10",
          "val2": "-7.20",
          "chgp": "-1,123.61%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "1.50",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-83.70",
          "val2": "-5.30",
          "chgp": "-1,479.25%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  }
]
Quarterly Results Snapshot (Consolidated) - Jun'25 - YoYstock-summary
Jun'25
Jun'24
Change(%)
Net Sales
0.00
0.00
Operating Profit (PBDIT) excl Other Income
-28.40
-2.70
-951.85%
Interest
0.00
0.00
Exceptional Items
0.00
-0.40
100.00%
Consolidate Net Profit
-24.60
-2.70
-811.11%
Operating Profit Margin (Excl OI)
0.00%
0.00%
NA
USD in Million.
stock-summary Compare with Peers
Net Sales

YoY Growth in quarter ended Jun 2025 is 0.00% vs 0.00% in Jun 2024

Direction Arrows
Consolidated Net Profit

YoY Growth in quarter ended Jun 2025 is -811.11% vs -80.00% in Jun 2024

All Quarterly Resultsstock-summary
Annual Results Snapshot (Consolidated) - Dec'24stock-summary
Dec'24
Dec'23
Change(%)
Net Sales
0.00
0.00
Operating Profit (PBDIT) excl Other Income
-88.10
-7.20
-1,123.61%
Interest
1.50
0.00
Exceptional Items
0.00
0.00
Consolidate Net Profit
-83.70
-5.30
-1,479.25%
Operating Profit Margin (Excl OI)
0.00%
0.00%
NA
USD in Million.
stock-summary Compare with Peers
Net Sales

YoY Growth in year ended Dec 2024 is 0.00% vs 0.00% in Dec 2023

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Dec 2024 is -1,479.25% vs 46.46% in Dec 2023

All Annual Resultsstock-summary
stock-summaryCompany CV
About ARCA biopharma, Inc. stock-summary
stock-summary
ARCA biopharma, Inc.
Pharmaceuticals & Biotechnology
ARCA biopharma, Inc. (ARCA) is a biopharmaceutical company. The Company is principally focused on developing genetically-targeted therapies for cardiovascular diseases. The Company's lead product candidate is Gencaro (bucindolol hydrochloride), a beta-blocker and mild vasodilator that the Company is evaluating in a clinical trial for the treatment of atrial fibrillation (AF) in patients with heart failure with reduced left ventricular ejection fraction (HFREF). Gencaro is considered part of the beta-blocker class of compounds because of its property of blocking both beta-1 and beta-2, receptors in the heart. The blocking of these receptors prevents the receptor from binding with other molecules, primarily the neurotransmitter norepinephrine (NE), which activate these receptors. The Company is conducting a Phase IIB/III clinical trial of Gencaro, known as GENETIC-AF.
Company Coordinates stock-summary
Company Details
10170 Church Ranch Way, Suite 100 , WESTMINSTER CO : 80021
stock-summary
Tel: 1 720 9402100
stock-summary
http://arcabio.com/
stock-summary
Registrar Details
Stock List
ABCDEFGHIJKLMNOPQRSTUVWXYZOther
Footer Logo
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
Market
Webinars
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."